Literature DB >> 21549584

Quality of spirometry tests performed by 9893 adults in 14 countries: the BOLD Study.

P Enright1, W M Vollmer, B Lamprecht, R Jensen, A Jithoo, W Tan, M Studnicka, P Burney, S Gillespie, A S Buist.   

Abstract

OBJECTIVE: to determine the ability of participants in the Burden of Obstructive Lung Disease (BOLD) study to meet quality goals for spirometry test session quality and to assess factors contributing to good quality.
METHODS: Following 2 days of centralized training, spirometry was performed pre- and post-bronchodilator (BD) at 14 international sites, in random population-based samples of persons aged ≥40 years, following a standardized protocol. The quality of each test session was evaluated by the spirometer software and an expert reading center. Descriptive statistics were calculated for key maneuver acceptability variables. A logistic regression model identified the predictors of acceptable quality test sessions.
RESULTS: About 96% of test sessions met our quality goals for a low back-extrapolated volume (BEV), time to peak flow (PEFT), and end-of-test volume (EOTV). The mean forced expiratory time (FET) was 10.4 s. Ninety percent of the maneuvers with the highest FVC had a forced expiratory time (FET) > 6.8 s. About 90% of test sessions had FEV(1) and FVC which were repeatable within 150 mL. Test quality was slightly better for post-BD test sessions when compared to pre-BD. Independent predictors of adequate test quality included female sex, younger age, higher education, lack of dyspnea, higher pre-BD FEV(1), less BD responsiveness, and study site.
CONCLUSIONS: Quality goals for spirometry tests were met about 90% of the time in these population-based samples of adults from several countries.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21549584     DOI: 10.1016/j.rmed.2011.04.008

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  7 in total

1.  Case-finding options for COPD: results from the Burden of Obstructive Lung Disease study.

Authors:  Anamika Jithoo; Paul L Enright; Peter Burney; A Sonia Buist; Eric D Bateman; Wan C Tan; Michael Studnicka; Filip Mejza; Suzanne Gillespie; William M Vollmer
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

2.  Forced expiratory time: a composite of airway narrowing and airway closure.

Authors:  Gwen S Skloot; Kieley L O'Connor-Chapman; Clyde B Schechter; Daniel J Markley; Jason H T Bates
Journal:  J Appl Physiol (1985)       Date:  2020-10-22

3.  Prevalence of chronic airflow limitation in Kashmir, North India: results from the BOLD study.

Authors:  P A Koul; N A Hakim; S A Malik; U H Khan; J Patel; L Gnatiuc; P G J Burney
Journal:  Int J Tuberc Lung Dis       Date:  2016-10       Impact factor: 2.373

4.  Assessing community (peer) researcher's experiences with conducting spirometry and being engaged in the 'Participatory Research in Ottawa: Management and Point-of-care for Tobacco-dependence' (PROMPT) project.

Authors:  Catherine B Charron; Alzahra Hudani; Tina Kaur; Tiffany Rose; Kelly Florence; Sadia Jama; Smita Pakhalé
Journal:  Res Involv Engagem       Date:  2018-12-01

5.  Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement.

Authors:  Brian L Graham; Irene Steenbruggen; Martin R Miller; Igor Z Barjaktarevic; Brendan G Cooper; Graham L Hall; Teal S Hallstrand; David A Kaminsky; Kevin McCarthy; Meredith C McCormack; Cristine E Oropez; Margaret Rosenfeld; Sanja Stanojevic; Maureen P Swanney; Bruce R Thompson
Journal:  Am J Respir Crit Care Med       Date:  2019-10-15       Impact factor: 21.405

6.  The Practical Significance of Measurement Error in Pulmonary Function Testing Conducted in Research Settings.

Authors:  Richard B Belzer; R Jeffrey Lewis
Journal:  Risk Anal       Date:  2019-06-03       Impact factor: 4.000

7.  Quality and learning aspects of the first 9000 spirometries of the LifeGene study.

Authors:  Mikaela Qvarfordt; Martin Anderson; Magnus Svartengren
Journal:  NPJ Prim Care Respir Med       Date:  2018-02-19       Impact factor: 2.871

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.